STAT+: Ouster of FDA\u2019s Peter Marks alarms a biopharma industry that saw him as an ally
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
When Robert F. Kennedy Jr., a longtime and visceral critic of pharmaceutical and biotech companies, was nominated by President Trump to be the nation\u2019s health secretary, the head of biotech\u2019s largest trade group issued a statement saying that he had \u201cevery confidence\u201d that the industry would \u201ccontinue to thrive and deliver\u201d on its goals, and looked forward to working closely with the new administration.<\/p>\n
Three months later, in February, when the National Institutes of Health announced plans to slash indirect cost payments to universities and other institutions that have received federal grants, the trade group, the Biotechnology Innovation Organization, issued no response<\/a>, even though the work of those universities and other institutions is a critical driver of new drugs and other medical products.<\/p>\n On Saturday, one day after news that the Food and Drug Administration\u2019s top vaccine regulator had been forced out of his post by Kennedy<\/a>, who has since been confirmed by the Senate as health secretary, BIO CEO John Crowley released a statement<\/a> saying that the group was \u201cdeeply concerned that the loss of experienced leadership at the FDA will erode scientific standards and broadly impact the development of new, transformative therapies to fight diseases for the American people.\u201d\u00a0<\/p>\n Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n